Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

Catalyst Pharmaceuticals (CPRX) announced that the company and its licensor SERB S.A. have entered into a Settlement Agreement with Teva ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - January 6 ...

The tech giant has released a new line of three 5G industrial edge routers and an IoT gateway series for IoT and edge use cases. Cisco has unveiled a new line of Catalyst industrial edge routers ...

especially for customers thinking about [use cases like] manufacturing,” he said. The Cisco IoT Operations Dashboard can now be used to manage the Catalyst IW9167 in wireless backhaul mode.

On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ ... Teva will not market its generic version of Firdapse in the United States before February 25, 2035, unless certain limited circumstances ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...